Donald E. Bobo, Jr. Sells 5,300 Shares of Edwards Lifesciences Corporation (EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction that occurred on Friday, July 28th. The stock was sold at an average price of $114.68, for a total value of $607,804.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Friday, August 4th, Donald E. Bobo, Jr. sold 25,000 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $116.00, for a total value of $2,900,000.00.
  • On Thursday, June 29th, Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $117.15, for a total value of $656,040.00.
  • On Monday, May 8th, Donald E. Bobo, Jr. sold 19,100 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $110.34, for a total value of $2,107,494.00.
  • On Thursday, May 4th, Donald E. Bobo, Jr. sold 34,120 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $109.98, for a total value of $3,752,517.60.

Edwards Lifesciences Corporation (EW) opened at 114.50 on Friday. The stock has a market capitalization of $24.18 billion, a P/E ratio of 34.73 and a beta of 0.63. Edwards Lifesciences Corporation has a 52-week low of $81.12 and a 52-week high of $121.75. The company’s 50-day moving average price is $116.95 and its 200 day moving average price is $105.35.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.20. Edwards Lifesciences Corporation had a return on equity of 27.17% and a net margin of 22.16%. The business had revenue of $842 million for the quarter, compared to the consensus estimate of $839.16 million. During the same quarter in the previous year, the company posted $0.76 earnings per share. Edwards Lifesciences Corporation’s revenue for the quarter was up 10.9% compared to the same quarter last year. On average, equities research analysts anticipate that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

WARNING: This news story was posted by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.com-unik.info/2017/08/12/donald-e-bobo-jr-sells-5300-shares-of-edwards-lifesciences-corporation-ew-stock-updated.html.

Several hedge funds and other institutional investors have recently modified their holdings of EW. BlackRock Inc. increased its position in shares of Edwards Lifesciences Corporation by 2,184.9% in the first quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock worth $1,317,326,000 after buying an additional 13,390,818 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Edwards Lifesciences Corporation by 161.7% in the second quarter. Bank of New York Mellon Corp now owns 5,304,536 shares of the medical research company’s stock worth $627,207,000 after buying an additional 3,277,726 shares in the last quarter. Egerton Capital UK LLP acquired a new position in shares of Edwards Lifesciences Corporation during the second quarter worth $217,805,000. Alliancebernstein L.P. increased its position in shares of Edwards Lifesciences Corporation by 29.8% in the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock worth $598,890,000 after buying an additional 1,459,921 shares during the period. Finally, MARSHALL WACE ASIA Ltd purchased a new position in shares of Edwards Lifesciences Corporation during the first quarter worth approximately $126,959,000. Institutional investors and hedge funds own 84.15% of the company’s stock.

Several research analysts have issued reports on the company. BidaskClub cut Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Canaccord Genuity reiterated a “buy” rating and issued a $150.00 price objective on shares of Edwards Lifesciences Corporation in a research report on Wednesday, June 28th. Zacks Investment Research upgraded Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $129.00 price objective for the company in a research report on Thursday, June 1st. Goldman Sachs Group, Inc. (The) assumed coverage on Edwards Lifesciences Corporation in a research report on Tuesday, May 16th. They issued a “conviction-buy” rating and a $138.00 price objective for the company. Finally, Cowen and Company reiterated an “outperform” rating and issued a $135.00 price objective (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research report on Thursday, July 27th. Five analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $121.13.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit